BridgeBio Pharma, Inc. 8-K

What Happened BridgeBio Pharma (BBIO) filed a Current Report on Form 8-K on May 13, 2026 (Item 8.01) to announce that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for encaleret for individuals living with ADH1. The company attached a press release titled “BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1” as Exhibit 99.1 to the filing.

Key Details

• Filing date: Form 8-K submitted on May 13, 2026 (Item 8.01 — Other Events).
• Event: NDA submission to the FDA for encaleret intended for individuals with ADH1.
• Press release: Titled “BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1” (Exhibit 99.1).
• Exhibits: Press release attached as Exhibit 99.1; inline XBRL cover page included (Exhibit 104).

Why It Matters An NDA submission is a major regulatory milestone that begins the FDA review process for potential approval. For investors, this advances BridgeBio’s development pipeline from clinical development toward commercialization for encaleret if the FDA accepts and ultimately approves the application. Key upcoming items investors may watch for are FDA acceptance of the filing, the agency’s review timeline (including any PDUFA date if set), and subsequent regulatory communications.